Natural Remedies has been awarded the 2026 ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award by the American Botanical Council (ABC) for its extensive commitment to clinical research on medicinal plants. Dr. Suresh Lakshmikanthan, the company’s chief business officer, accepted the award during the Botanical Excellence Awards ceremony at Natural Products Expo West. Mark Blumenthal, founder of ABC, highlighted Natural Remedies’ rigorous scientific approach, which bridges traditional herbal knowledge with modern clinical evidence, particularly in the study of botanicals like holy basil, turmeric, bacopa, andrographis, and licorice.

This recognition underscores the significance of Natural Remedies’ contributions to the field, particularly its 20+ published human clinical trials that explore the health benefits of these botanicals. The company has successfully documented applications for conditions such as cognitive function, digestive health, stress resilience, and joint comfort, thereby reinforcing the therapeutic potential of these plants within the context of both traditional Indian medicine and contemporary health challenges. Their innovative products, including Bacomind and GutGard, are grounded in robust clinical and preclinical research, showcasing a commitment to evidence-based solutions in the herbal sector.

The implications of this award extend beyond recognition; it sets a precedent for the herbal industry by emphasizing the need for scientific rigor and transparency in product development. As Natural Remedies continues to advance its research-driven approach, it may influence other companies to adopt similar methodologies, ultimately accelerating the timeline for bringing clinically validated herbal therapies to market. This shift could enhance the credibility of herbal medicine as a viable option in integrative health strategies, aligning with the growing demand for substantiated natural health products.

Source: globenewswire.com